DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...
Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...
DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening ...
Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.
FDA clears Dexcom Stelo as the first OTC CGM for children, raising new questions around app access, caregiver oversight, school device rules, and reimbursement.
Bell Global Equities Fund, managed by Bell Asset Management, released its May investor update. A copy of the letter can be ...
Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) reported new clinical data from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results